3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Stomach Neoplasms
1
Rare Tumour
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Locally Advanced Prostate Cancer
1
Limited Stage Small Cell Lung Cancer
1
Hereditary leiomyomatosis and renal cell cancer
1
HER2-negative Breast Cancer
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Interventions
Nivolumab
5
olaparib
3
Specimen Handling
3
Paclitaxel
3
durvalumab
2
cediranib
2
Magnetic Resonance Spectroscopy
2
Carboplatin
2
Biopsy
2
rucaparib
1
pazopanib
1
pamiparib
1
liposomal doxorubicin
1
ceralasertib
1
capivasertib
1
cabozantinib
1
apatinib
1
Trabectedin
1
Ipilimumab
1
Immunoglobulin G
1
Gemcitabine
1
Fluid Therapy
1
Disulfides
1
Cisplatin
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinosarcoma
×
pamiparib
×
Clear all
NCT03933761
2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2
Withdrawn